論文

査読有り
2019年9月

Soluble Interleukin-2 Receptor Level at Diagnosis Predicts Prognosis of Patients With Follicular Lymphoma Irrespective of Initial Management Strategy.

Anticancer Res.
  • Masahide Yamamoto
  • ,
  • Keisuke Tanaka
  • ,
  • Yoshihiro Umezawa
  • ,
  • Toshikage Nagao
  • ,
  • Shigeo Toyota
  • ,
  • Osamu Miura

39
9
開始ページ
5115
終了ページ
5122
記述言語
英語
掲載種別
DOI
10.21873/anticanres.13706

Although various prognostic indices for follicular lymphoma (FL) have been proposed, they are designed specifically for patients requiring immediate therapy. We aimed to develop a new simple prognostic tool applicable for all patients with FL at diagnosis.<br />
We retrospectively analyzed various clinical, pathological, and laboratory data, including soluble interleukin-2 receptor (sIL2R), from 140 patients with FL from two centers for their impact on prognosis. This study analyzed the impact of soluble interleukin-2 receptor (sIL2R) in order to develop a new simple prognostic tool applicable for all patients with FL at diagnosis.<br />
The initial management of these patients was watchful waiting (n=48) or immediate treatment (n=92). Event-free survival at 24 months predicted overall survival. When categorized into three groups according to the sIL2R levels at diagnosis, a very high sIL2R level identified about 20% of patients with a distinctively worse survival compared to the others.<br />
sIL2R is a very effective biomarker that can be easily applied in routine practice to predict survival for all patients with FL at diagnosis irrespective of initial management approach.

リンク情報
DOI
https://doi.org/10.21873/anticanres.13706
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/31519623